Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Receptors, Cell Surface”

39 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 39 results

Not applicableStudy completedNCT03727113
What this trial is testing

Optimization of Antibiotic Treatment in Hematopoietic Stem Cell Receptors

Who this might be right for
Hematopoietic Stem Cell TransplantationGraft Versus Host Disease
Fundación Pública Andaluza para la gestión de la Investigación en Sevilla 211
Not applicableNo Longer AvailableNCT04194190
What this trial is testing

A Single Patient Will be Treated With Individual Patient TCR-Transduced PBL

National Institutes of Health Clinical Center (CC)
Testing effectiveness (Phase 2)Ended earlyNCT03709706
What this trial is testing

Pilot Immunotherapy Study With Letetresgene Autoleucel (Lete-cel, GSK3377794)T-cells in New York Esophageal Squamous Cell Carcinoma-1 (NY-ESO-1)/ LAGE-1a-positive Advanced Non-small Cell Lung Cancer (NSCLC) Either Alone or in Combination With Pembrolizumab

Who this might be right for
Neoplasms
GlaxoSmithKline 34
Testing effectiveness (Phase 2)Active Not RecruitingNCT03967223
What this trial is testing

Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Solid Tumors

Who this might be right for
Neoplasms
USWM CT, LLC 103
Testing effectiveness (Phase 2)Looking for participantsNCT05972135
What this trial is testing

Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma

Who this might be right for
Multiple Myeloma
SCRI Development Innovations, LLC 100
Early research (Phase 1)Looking for participantsNCT00595491
What this trial is testing

Pilot Study to Identify the Mediators and Inflammatory Cell Surface Receptors Involved in Allergic Airway Inflammation

Who this might be right for
Asthma
Benjamin Medoff 313
Not applicableStudy completedNCT02615951
What this trial is testing

Characterization of Breg Cells

Who this might be right for
Healthy VolunteersArthritis, Rheumatoid
University Hospital, Montpellier 100
Not applicableNo Longer AvailableNCT04135092
What this trial is testing

Single Patient Protocol: A Phase II Study Using the Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Mutated Neoantigens in a Patient With Metastatic Cancer Plus the Administration of Pembrolizumab

National Institutes of Health Clinical Center (CC)
Not applicableStudy completedNCT04994093
What this trial is testing

Creating an Innovative AI-based Technology TCRact for Designing and Optimizing T-cell Receptors (TCR) for Use in Cancer Immunotherapies

Who this might be right for
Colon CancerCancer
Ardigen 118
Early research (Phase 1)Ended earlyNCT04526509
What this trial is testing

Master Protocol to Assess Safety and Dose of First Time in Human Next Generation Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Advanced Solid Tumors

Who this might be right for
Neoplasms
Adaptimmune 12
Large-scale testing (Phase 3)Active Not RecruitingNCT06074588
What this trial is testing

Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)

Who this might be right for
Non-small Cell Lung Cancer (NSCLC)
Merck Sharp & Dohme LLC 556
Large-scale testing (Phase 3)Looking for participantsNCT07613307
What this trial is testing

Orforglipron (LY3502970) in Participants With Type 2 Diabetes Who Observe Ramadan Fasting

Who this might be right for
Diabetes Mellitus, Type 2Diabetes MelletusGlucose Metabolism Disorders+13 more
Eli Lilly and Company 130
Early research (Phase 1)Study completedNCT02776813
What this trial is testing

Study of ACTR087 in Subjects With Relapsed or Refractory B-cell Lymphoma

Who this might be right for
Lymphoma
Cogent Biosciences, Inc. 34
Not applicableEnded earlyNCT03391791
What this trial is testing

Long Term Follow up of Subjects Exposed to Genetically Engineered T Cell Receptors

Who this might be right for
Solid and Hematological Malignancies
Adaptimmune 2
Early research (Phase 1)Looking for participantsNCT06942143
What this trial is testing

An Open-label, Phase I Clinical Trial of Super1 TCR-T in NY-ESO-1-positive Patients With Advanced Solid Tumors

Who this might be right for
SarcomaLung CancersMelanoma
Guangzhou FineImmune Biotechnology Co., LTD. 15
Early research (Phase 1)Study completedNCT00004178
What this trial is testing

Gene Therapy in Treating Patients With Cancer

Who this might be right for
Cancer
Roger Williams Medical Center
Testing effectiveness (Phase 2)Looking for participantsNCT06406465
What this trial is testing

A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity

Who this might be right for
Carcinoma, NeuroendocrineTumor, NeuroendocrineTumors, Neuroendocrine+2 more
National Cancer Institute (NCI) 60
Testing effectiveness (Phase 2)Ended earlyNCT05100316
What this trial is testing

Screening Protocol for Preliminary Eligibility Determination for Adoptive Cell Therapy Trials

Who this might be right for
Neoplasms
GlaxoSmithKline 16
Early research (Phase 1)Study completedNCT00085930
What this trial is testing

Blood T-Cells and EBV Specific CTLs Expressing GD-2 Specific Chimeric T Cell Receptors to Neuroblastoma Patients

Who this might be right for
Neuroblastoma
Baylor College of Medicine 19
Testing effectiveness (Phase 2)WithdrawnNCT04536922
What this trial is testing

Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Mutated or Viral Neoantigens in a Patient With Metastatic Cancer Plus the Administration of Pembrolizumab

Who this might be right for
Metastatic HPV-16 Positive Squamous Cell Anal Cancer
National Cancer Institute (NCI)
Next Page